TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03497273
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
Study: NCT00852579
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily dose 250mg
Study: NCT00852579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02462187
Drug: NVN1000 8% Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: once and twice daily
Study: NCT02462187
Drug: NVN1000 16%
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT02462187
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT02462187
Drug: NVN1000 24%
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00728156
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
Study: NCT01323985
Drug: GSK2315698
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg-400mg IV (in the vein) single dose over 1-4 hours
Study: NCT01323985
Drug: GSK2315698
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV (in the vein) single dose over 24 hours, in two sessions
Study: NCT01861561
Drug: Low-dose intravenous cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
Study: NCT01861561
Drug: High-dose intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose
Study: NCT03968302
Drug: ARM A Triple therapy for helicobacter pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
Study: NCT03968302
Drug: ARM B Quadruple therapy for helicobacter pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
Study: NCT00194467
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo, once a day for 8 weeks
Study: NCT02440204
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
Study: NCT01142076
Drug: Xinju Xiaogao Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment group
Study: NCT01142076
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of 10%
Study: NCT03723798
Drug: SA001 Mid dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets b.i.d for 12 weeks
Study: NCT03723798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets b.i.d for 12 weeks
Study: NCT00347932
Drug: ISV-403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
Study: NCT00347932
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
Study: NCT03318354
Drug: Daiichi Sankyo Inc's Benicar Tablets 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02176850
Drug: Micardis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04039412
Drug: Hybrid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: two-step (dual-quadruple) treatment
Study: NCT04039412
Drug: Reverse hybrid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: one-step two-phase (quadruple-dual) treatment
Study: NCT02197806
Drug: AGN-199201
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
Study: NCT02197806
Drug: AGN-190584
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
Study: NCT02197806
Drug: AGN-199201 Vehicle
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
Study: NCT01420445
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times daily / 7 days
Study: NCT02046460
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid, 300mg o.p.d.
Study: NCT02046460
Drug: Vitamin K antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K-antagonists, target INR 2.0-3.0
Study: NCT00368654
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dose 5 mg, then 15 mg per week
Study: NCT03891420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusion
Study: NCT01946373
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01680718
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
Study: NCT01581307
Drug: FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.
Study: NCT02368795
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 100 mg suppository ten minutes before ERCP
Study: NCT02368795
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
Study: NCT01754844
Drug: AZD7624
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose inhaled IMP via a nebulizer
Study: NCT01754844
Drug: Placebo to match
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose inhaled Placebo via a nebulizer
Study: NCT01831154
Drug: Standard Glycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin was Regular Insulin administered intravenous bolus.
Study: NCT00642239
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
Study: NCT00768300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ambrisentan was administered orally once daily.
Study: NCT02439905
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
Study: NCT03249311
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Study: NCT02439307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 2 weeks
Study: NCT04098302
Drug: Placebo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules with matching appearance as Dutasteride Capsules
Study: NCT03175341
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.
Study: NCT03175341
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml normal saline 0.9%
Study: NCT03225248
Drug: UI05MSP015CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: UI05MSP015CT and Placebo of Gasmotin
Study: NCT01555489
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3x per week
Study: NCT03867682
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.
Study: NCT01460069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
Study: NCT03326063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
Study: NCT01989429
Drug: M518101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
Study: NCT04541485
Drug: DWRX2003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly injection at pre-defined injection sites
Study: NCT04541485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly injection at pre-defined injection sites
Study: NCT02830919
Drug: Glucosamine and chondroitin sulfate combination (Eurofarma)
Normalized name: chondroitin sulfates / glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02830919
Drug: Glucosamine and chondroitin sulfate combination (Zodic)
Normalized name: chondroitin sulfates / glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01984047
Drug: GSK3050002
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
Study: NCT01984047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
Study: NCT00222144
Drug: Gleevec and Taxotere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
Study: NCT00989508
Drug: Placebo marked PEXSIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
Study: NCT04061109
Drug: Recombinant Human Coagulation FVIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
Study: NCT02524561
Drug: CEE pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.45 mg/day
Study: NCT02524561
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climara 50 mcg/day
Study: NCT02099084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching study drug, administered subcutaneously.
Study: NCT02379195
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
Study: NCT03894696
Drug: Direct Acting Antivirals
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: follow up chronic HCV patients recieving DAAs to detect anxiety and depression
Study: NCT03489044
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
Study: NCT02091635
Drug: Placebo (for Motilitone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
Study: NCT02091635
Drug: Motilitone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
Study: NCT00003631
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00996658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching linagliptin tablets once daily
Study: NCT03888378
Drug: 0.3% Topical Minocycline Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
Study: NCT03888378
Drug: 1% Topical Minocycline Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
Study: NCT00907985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo will be provided.
Study: NCT00374296
Drug: MGCD0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGCD0103 administered orally three-times per week
Study: NCT05051241
Drug: GFH018
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.
Study: NCT00650663
Drug: Ezetimibe + Simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
Study: NCT00650663
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet; simvastatin 20 mg once daily for 12 weeks
Study: NCT04224922
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00973336
Drug: Calcium and vitamin D
Normalized name: Wellesse Calcium and Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg calcium per day 800 IE vitamin D per day
Study: NCT00997984
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosed in the AM or PM
Study: NCT01926444
Drug: GIC-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIC-1001 oral tablet, white-coated, to be taken with water
Study: NCT00821158
Drug: Antioxidant
Normalized name: ANTIOXIDANT GS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant iv bolus
Study: NCT00821158
Drug: Anti-inflammatory drug
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory tablet
Study: NCT00093262
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04430361
Drug: 5-HT3 receptor antagonist
Normalized name: 5-HT3 receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT3 receptor antagonist 2.5mg/iv
Study: NCT00135460
Drug: nucleoside analogue sparing HAART regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01279876
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3mg oral, daily, one hour before sleep
Study: NCT01715363
Drug: Fluorouracile
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01724229
Drug: Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01999686
Drug: DLBS3233
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01999686
Drug: Placebo DLBS3233
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
Study: NCT02185053
Drug: CPC-201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02544750
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT00705770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with vehicle
Study: NCT00429871
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
Study: NCT01537471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01393899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets twice daily
Study: NCT01393899
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets twice daily
Study: NCT02503085
Drug: Nurofen for Children®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02503085
Drug: Algifor Dolo Junior®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02538536
Drug: PBI4050
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01460706
Drug: [68Ga]DOTATOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
Study: NCT00886769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
Study: NCT00498043
Drug: R-CHOP14 induction regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP14 induction regimen
Study: NCT00498043
Drug: R-ACVBP14 induction regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-ACVBP14 induction regimen
Study: NCT00673179
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m\^2.
Study: NCT00673179
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m\^2, max 20 gm over 4 hours.
Study: NCT00673179
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
Study: NCT00651755
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 By Vein On Day 1
Study: NCT00651755
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 By Vein Over 48 Hours On Days 1-2
Study: NCT00536172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo distribution matches the active medication.
Study: NCT01751776
Drug: Placebo matching BI 655064
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 655064 injected subcutaneous.
Study: NCT00281684
Drug: SB705498 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB705498 400 mg
Study: NCT00281684
Drug: SB705498 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB705498 1000 mg
Study: NCT00281684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00281684
Drug: Co-Codamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-Codamol
Study: NCT03006159
Drug: SHR0534
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03006159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05422677
Drug: Hanmi Tams® Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hanmi Tams®, Once daily administered per the locally approved product information
Study: NCT02742987
Drug: Standard medical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Study: NCT03807011
Drug: fentanyl group
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl 2 μg/kg
Study: NCT03807011
Drug: remifentanil group
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 0.2 μg/kg/min
Study: NCT04287777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of Placebo (ointment) TID during 7 days
Study: NCT04571710
Drug: SHR1258
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR1258 400mg
Study: NCT01217970
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no